Advertisement
ABSI vs DNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Hold and DNA is a Buy.
ABSI sees its Stochastic Oscillator ascends from oversold territory
On November 09, 2026, the Stochastic Oscillator for ABSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 59 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
ABSI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 20 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +15.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 141 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 85 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.498). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 68 cases where DNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNA as a result. In 81 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 47 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.498). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ABSI | DNA | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 88% |
| Advances ODDS (%) | 3 days ago 90% | 3 days ago 84% |
| Declines ODDS (%) | 10 days ago 88% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | N/A |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABSI’s FA Score shows that 0 FA rating(s) are green while DNA’s FA Score has 0 green FA rating(s).
- ABSI’s FA Score: 0 green, 5 red.
- DNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABSI’s TA Score shows that 5 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).
- ABSI’s TA Score: 5 bullish, 5 bearish.
- DNA’s TA Score: 5 bullish, 3 bearish.
Price Growth
ABSI (@Biotechnology) experienced а -0.30% price change this week, while DNA (@Biotechnology) price change was +11.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ABSI is expected to report earnings on Nov 12, 2026.
DNA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ABSI and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABSI has been loosely correlated with CRSP. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ABSI jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To ABSI | 1D Price Change % | ||
|---|---|---|---|---|
| ABSI | 100% | +1.50% | ||
| CRSP - ABSI | 60% Loosely correlated | +1.33% | ||
| RXRX - ABSI | 60% Loosely correlated | +1.13% | ||
| ABCL - ABSI | 57% Loosely correlated | -4.09% | ||
| BEAM - ABSI | 55% Loosely correlated | +2.62% | ||
| NTLA - ABSI | 53% Loosely correlated | +2.15% | ||
More | ||||
DNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -14.65% | ||
| TWST - DNA | 63% Loosely correlated | -7.22% | ||
| RXRX - DNA | 61% Loosely correlated | +1.13% | ||
| VCYT - DNA | 58% Loosely correlated | +4.36% | ||
| ABSI - DNA | 53% Loosely correlated | +1.50% | ||
| NTLA - DNA | 53% Loosely correlated | +2.15% | ||
More | ||||